[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100593295":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":32,"locations":41,"responsibleParty":115,"collaborators":117,"id":122,"slug":123,"hasResults":124,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":124,"sex":130,"minAge":131,"maxAge":10,"enrollmentInfo":132,"targetDuration":10,"studyType":135,"phases":10,"briefSummary":136,"conditions":137,"keywords":142,"overallStatus":95,"whyStopped":10,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":169},{"fullName":5,"class":6},"Maastricht Radiation Oncology","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"HDR brachytherapy",null,"High-risk or recurrent prostate cancer patients that will undergo high dose rate (HDR) brachytherapy.",[13],"Procedure: HDR brachytherapy",{"label":15,"type":10,"description":16,"interventionNames":17},"Diagnostic biopsy","Patients with MRI-suspected metastatic prostate cancer - with at least clinical stage T3-4 disease - that will undergo a diagnostic transperineal prostate biopsy procedure guided with ultrasound (i.e., targeted or template prostate cancer needle biopsies taken through the perineum guided with transrectal ultrasound)",[18],"Diagnostic Test: Diagnostic biopsy",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":10},"PROCEDURE","High dose rate (HDR) brachytherapy for the treatment of high-risk or recurrent prostate cancer",[9],{"type":25,"name":15,"description":26,"armGroupLabels":27,"otherNames":10},"DIAGNOSTIC_TEST","Transperineal prostate biopsies guided with transrectal ultrasound for the diagnosis of (recurrent) prostate cancer",[15],[29],{"name":30,"affiliation":5,"role":31},"Evert J Van Limbergen, PhD, MD","PRINCIPAL_INVESTIGATOR",[33,38],{"name":34,"role":35,"phone":36,"phoneExt":10,"email":37},"Iris EWG Laven, PhD","CONTACT","0031(0)884455666","iris.laven@maastro.nl",{"name":39,"role":35,"phone":36,"phoneExt":10,"email":40},"Chantal Overhof, BEc","groepcto@maastro.nl",[42,71,94],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Zuyderland Medisch Centrum","NOT_YET_RECRUITING","Heerlen","Limburg","6419 PC","Netherlands","NL",{"type":51,"coordinates":52},"Point",[53,54],5.98154,50.88365,{"lat":54,"lon":53},[57,61,64,65,67,69],{"name":58,"role":35,"phone":59,"phoneExt":10,"email":60},"Lizzy EJM Driessen, PhD","0031 (0) 88 459 7777","li.driessen@zuyderland.nl",{"name":62,"role":35,"phone":59,"phoneExt":10,"email":63},"Max H Bruins, PhD, MD","m.bruins@zuyderland.nl",{"name":62,"role":31,"phone":10,"phoneExt":10,"email":10},{"name":58,"role":66,"phone":10,"phoneExt":10,"email":10},"SUB_INVESTIGATOR",{"name":68,"role":66,"phone":10,"phoneExt":10,"email":10},"Ruud J Clarijs, PhD, MD",{"name":70,"role":66,"phone":10,"phoneExt":10,"email":10},"Franchette WPJ Van den Berkmortel, PhD, MD",{"facility":72,"status":44,"city":73,"state":46,"zip":74,"country":48,"countryCode":49,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Academisch Ziekenhuis Maastricht","Maastricht","6229 ET",{"type":51,"coordinates":76},[77,78],5.68889,50.84833,{"lat":78,"lon":77},[81,85,88,89,90,92],{"name":82,"role":35,"phone":83,"phoneExt":10,"email":84},"Joep GH Van Roermund, PhD, MD","0031 (0)43 387 6543","joep.van.roermund@mumc.nl",{"name":86,"role":35,"phone":83,"phoneExt":10,"email":87},"Thomas MA Kerkhofs, PhD, MD","thomas.kerkhofs@mumc.nl",{"name":82,"role":31,"phone":10,"phoneExt":10,"email":10},{"name":86,"role":66,"phone":10,"phoneExt":10,"email":10},{"name":91,"role":66,"phone":10,"phoneExt":10,"email":10},"Tom AT Marcelissen, PhD, MD",{"name":93,"role":66,"phone":10,"phoneExt":10,"email":10},"Iryna V Samarska, PhD, MD",{"facility":5,"status":95,"city":73,"state":46,"zip":74,"country":48,"countryCode":49,"cosmosGeoPoint":96,"geoPoint":98,"contacts":99},"RECRUITING",{"type":51,"coordinates":97},[77,78],{"lat":78,"lon":77},[100,102,105,106,107,109,111,113],{"name":34,"role":35,"phone":101,"phoneExt":10,"email":37},"0031 (0) 88 44 55 666",{"name":30,"role":35,"phone":103,"phoneExt":10,"email":104},"0031 (0)88 44 55 666","evert.vanlimbergen@maastro.nl",{"name":34,"role":66,"phone":10,"phoneExt":10,"email":10},{"name":30,"role":31,"phone":10,"phoneExt":10,"email":10},{"name":108,"role":66,"phone":10,"phoneExt":10,"email":10},"Dirk KM De Ruysscher, Prof, MD",{"name":110,"role":66,"phone":10,"phoneExt":10,"email":10},"Rianne DW Vaes, PhD",{"name":112,"role":66,"phone":10,"phoneExt":10,"email":10},"Kasper MA Rouschop, Prof",{"name":114,"role":66,"phone":10,"phoneExt":10,"email":10},"Marc AGG Vooijs, Prof",{"type":116,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[118,120],{"name":119,"class":6},"Zuyderland Medical Centre",{"name":121,"class":6},"Maastricht University Medical Center","100593295","lab-research-using-mini-tumors-to-study-prostate-cancer-treatments-100593295",false,"NCT07004582","Lab Research Using Mini-tumors to Study Prostate Cancer Treatments","Preclinical ex Vivo Patient-derived 3D Cultures for the Prediction of Prostate Cancer Treatment Response","PR3DICT","Inclusion Criteria:\n\n* Patients aged 18 years or older\n* Patients with prostate cancer\n* Patients planned for HDR brachytherapy treatment for high-risk or recurrent prostate cancer or transperineal prostate biopsy with MRI-suspected metastatic prostate cancer with at least clinical stage T3-4.\n\nExclusion Criteria:\n\n* Patients younger than 18 years\n* Patients of whom it is not possible to obtain left-over tissue as part of the normal clinical treatment procedure (e.g., if all tumor material is required for the pathologist to make a diagnosis, to stage the patient or to perform a molecular diagnosis).","MALE","18 Years",{"count":133,"type":134},600,"ESTIMATED","OBSERVATIONAL","For men with an aggressive form of prostate cancer, finding the right and effective treatment right away is challenging. Many of these men face a high risk of cancer recurrence: about half experience a relapse after surgery, and more than a third after undergoing radiation therapy. Men with metastatic prostate cancer have particularly poor prognoses, with a five-year survival rate of only 30% to 50%. In short, it is difficult to predict which treatment, or combination of treatments, will lead to longer survival for this group of men with aggressive (metastatic) prostate cancer.\n\nIn the laboratory, it is possible to grow small samples of tumors into 3D mini-tumors. These mini-tumors retain the characteristics of the patient's original tumor tissue. Various treatments can be tested on these 3D mini-tumors to determine which therapy is most effective for each individual case. There are currently two techniques available for creating these 3D mini-tumors in the lab. In this project, we aim to investigate which of these two techniques works best in order to test and personalize treatments.",[138,139,140,141],"Prostate Cancer","Prostate Cancer Metastatic Disease","Prostate Cancer Recurrent","Advanced Prostate Cancer",[143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159],"Advanced prostate cancer","Metastatic prostate cancer","Prostate cancer","Patient-tailored treatment","Precision Medicine","Ex vivo prediction platform","Personalized medicine","Drug Screening Assays","Three-Dimensional Culture Techniques","Organoids","Tumoroids","Tumor replicas","Prostatic Neoplasms","Neoplasm Metastasis","Advanced Cancer","Treatment Outcome","Human Tissue Culture Techniques","2026-04-20",{"date":162,"type":163},"2026-04-23","ACTUAL",{"date":165,"type":163},"2026-03-15",{"date":167,"type":134},"2031-12-30",{"name":5,"class":6},3]